Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 21,661 | 26,712 | 26,199 | 31,874 | 39,979 |
| TOTAL | $22,886 | $28,254 | $27,893 | $33,648 | $42,469 |
| Non-Current Assets | |||||
| PPE Net | 115 | 120 | 126 | 131 | 137 |
| Other Non-Current Assets | 1,662 | 2,120 | 6,687 | 6,697 | 4,423 |
| TOTAL | $1,777 | $2,240 | $6,813 | $6,828 | $4,560 |
| Total Assets | $24,663 | $30,494 | $34,706 | $40,476 | $47,029 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,650 | 3,574 | 5,181 | 4,497 | 2,859 |
| Accrued Expenses | 1,259 | 742 | 2,104 | 1,482 | 2,847 |
| TOTAL | $10,147 | $9,483 | $13,330 | $11,532 | $18,265 |
| Non-Current Liabilities | |||||
| Long Term Debt | 10,606 | 11,733 | 11,889 | 12,944 | 6,352 |
| TOTAL | $10,624 | $11,759 | $11,923 | $12,985 | $6,401 |
| Total Liabilities | $20,770 | $21,242 | $25,252 | $24,516 | $24,666 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 55,816 | 55,816 | 48,980 | 46,633 | 45,710 |
| Common Shares | 18 | 18 | 16 | 15 | 15 |
| Retained earnings | -223,956 | -216,607 | -209,044 | -200,034 | -190,600 |
| TOTAL | $3,893 | $9,252 | $9,454 | $15,960 | $22,362 |
| Total Liabilities And Equity | $24,663 | $30,494 | $34,706 | $40,476 | $47,029 |